

FDA approves Alexion's Soliris to treat adults with neuromyelitis optica spectrum disorder

This article was originally published [here](#)

The NMOSD is a rare and severe autoimmune disease, which attacks the central nervous system without warning. Also referred as relapses, the attacks may result in progressive and

The post [FDA approves Alexion's Soliris to treat adults with neuromyelitis optica spectrum disorder](#) appeared first on [Pharmaceutical Business review](#).